Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma

被引:53
|
作者
Chung, Brian K. [1 ,2 ,3 ,4 ,5 ]
Karlsen, Tom Hemming [3 ,4 ,5 ,6 ]
Folseraas, Trine [3 ,4 ,5 ,6 ]
机构
[1] Univ Birmingham, Ctr Liver Res, Birmingham, W Midlands, England
[2] Univ Birmingham, Inst Immunol & Immunotherapy, NIHR Birmingham Inflammat Biomed Res Ctr, Birmingham, W Midlands, England
[3] Oslo Univ Hosp, Div Surg Inflammatory Med & Transplantat, Dept Transplantat Med, Norwegian PSC Res Ctr,Rikshosp, Postboks 4950, N-0424 Oslo, Norway
[4] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway
[5] Oslo Univ Hosp, Div Surg Inflammatory Med & Transplantat, Internal Med Res Inst, Rigshosp, Oslo, Norway
[6] Univ Oslo, Inst Clin Med, Fac Med, KG Jebsen Inflammat Res Ctr, Oslo, Norway
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2018年 / 1864卷 / 04期
关键词
Primary sclerosing cholangitis; Cholangiocytes; Cholangiocarcinoma; Pathogenesis; INDUCE CYCLOOXYGENASE-2 EXPRESSION; CANCER-ASSOCIATED FIBROBLASTS; PRIMARY BILIARY-CIRRHOSIS; ENDOTHELIAL GROWTH-FACTOR; GENOME-WIDE ASSOCIATION; NATURAL-HISTORY; BILE-ACIDS; RISK-FACTORS; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA;
D O I
10.1016/j.bbadis.2017.08.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Primary sclerosing cholangitis (PSC) is an idiopathic cholangiopathy strongly associated with inflammatory bowel disease (IBD) and characterized by cholestasis, chronic immune infiltration and progressive fibrosis of the intrahepatic and extrahepatic bile ducts. PSC confers a high risk of cholangiocarcinoma (CCA) with PSC-CCA representing the leading cause of PSC-associated mortality. PSC-CCA is derived from cholangiocytes and associated progenitor cells a heterogeneous group of dynamic epithelial cells lining the biliary tree that modulate the composition and volume of bile production by the liver. Infection, inflammation and cholestasis can trigger cholangiocyte activation leading to an increased expression of adhesion and antigen-presenting molecules as well as the release of various inflammatory and fibrogenic mediators. As a result, activated cholangiocytes engage in a myriad of cellular processes, including hepatocellular proliferation, apoptosis, angiogenesis and fibrosis. Cholangiocytes can also regulate the recruitment of immune cells, mesenchymal cells, and endothelial cells that participate in tissue repair and destruction in settings of persistent inflammation. In PSC, the role of cholangiocytes and the mechanisms governing their transformation to PSC-CCA are unclear however localization of disease suggests that cholangiocytes are a key target and potential regulator of hepatobiliary immunity, fibrogenesis and tumorigenesis. Herein, we summarize mechanisms of cholangiocyte activation in PSC and highlight new insights into disease pathways that may contribute to the development of PSC-CCA. This article is. part of a Special Issue entitled: Cholangiocytes in Health and Disease edited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
引用
收藏
页码:1390 / 1400
页数:11
相关论文
共 50 条
  • [41] Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance
    Ehlken, Hanno
    Zenouzi, Roman
    Schramm, Christoph
    CURRENT OPINION IN GASTROENTEROLOGY, 2017, 33 (02) : 78 - 84
  • [42] Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis
    Fevery, Johan
    Verslype, Chris
    Lai, Gillian
    Aerts, Raymond
    Van Steenbergen, Werner
    DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (11) : 3123 - 3135
  • [43] Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review
    Junmin Song
    Yang Li
    Christopher L. Bowlus
    GuoXiang Yang
    Patrick S. C. Leung
    M. Eric Gershwin
    Clinical Reviews in Allergy & Immunology, 2020, 58 : 134 - 149
  • [44] Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis
    Villard, Christina
    Friis-Liby, Ingalill
    Rorsman, Fredrik
    Said, Karouk
    Warnqvist, Anna
    Cornillet, Martin
    Kechagias, Stergios
    Nyhlin, Nils
    Werner, Marten
    Janczewska, Izabella
    Hagstrom, Therese
    Nilsson, Emma
    Bergquist, Annika
    JOURNAL OF HEPATOLOGY, 2023, 78 (03) : 604 - 613
  • [45] Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
    Bernuzzi, F.
    Marabita, F.
    Lleo, A.
    Carbone, M.
    Mirolo, M.
    Marzioni, M.
    Alpini, G.
    Alvaro, D.
    Boberg, K. M.
    Locati, M.
    Torzilli, G.
    Rimassa, L.
    Piscaglia, F.
    He, X. -S.
    Bowlus, C. L.
    Yang, G. -X.
    Gershwin, M. E.
    Invernizzi, P.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2016, 185 (01) : 61 - 71
  • [46] Incidence, Diagnosis, and Therapy of Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis
    Johan Fevery
    Chris Verslype
    Gillian Lai
    Raymond Aerts
    Werner Van Steenbergen
    Digestive Diseases and Sciences, 2007, 52 : 3123 - 3135
  • [47] Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?
    Roger W Chapman
    Kate D. Williamson
    Current Hepatology Reports, 2017, 16 (2) : 124 - 129
  • [48] Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis
    Andreas, Wannhoff
    Daniel, Gotthardt N.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (03) : 236 - 243
  • [49] Cholangiocarcinoma and High-Grade Dysplasia in Young Patients with Primary Sclerosing Cholangitis
    Liu, Roy
    Cox, Kristen
    Guthery, Stephen L.
    Book, Linda
    Witt, Benjamin
    Chadwick, Barbara
    Adler, Douglas G.
    DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (09) : 2320 - 2324
  • [50] Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma
    Kerr, Sarah E.
    Fritcher, Emily G. Barr
    Campion, Michael B.
    Voss, Jesse S.
    Kipp, Benjamin R.
    Halling, Kevin C.
    Lewis, Jason T.
    HUMAN PATHOLOGY, 2014, 45 (09) : 1797 - 1804